Disclaimer:  The following information is drawn from materials prepared by candidates for promotion to full professor.  It is intended to illustrate activities and materials that might support promotion.  In using these materials, please note the following:

               *The Provost (and, in some cases, the President) are the University officers authorized to approve promotions.  All levels of review below these officers are advisory.

               *Only Departments are empowered to propose promotions, and the Divisional Dean is charged with transmitting such proposals to the Provost or returning them to the Department.

*The judgment of the Department, Dean, and Provost will therefore be critical to assessing qualification for promotion.

               *Materials considered by the Department, Dean, and Provost will also (and always) include confidential evaluations obtained from outside the University.  Materials considered by the Provost will include the confidential evaluations of the Dean and Department, and those considered by the Dean will include the confidential evaluations of the Department.

               *Thus, the following materials are ONLY PART of a complete proposal for promotion, whereas promotion is based on the ENTIRE proposal.   Therefore, it should not be assumed that a record comparable to that below will necessarily result in promotion, or that a record not comparable to that below will fail to result in promotion.  The Departmental Chair is likely to be the best source of advice as to whether promotion is feasible and, when it is not, what additional activity may result in qualification for promotion.

               *This document has been prepared as a tool for use by associate professors in the Division of the Biological Sciences.  Other individuals who may find it informative are Department Chairmen, Section Heads, Committee Chairmen, senior faculty and potential recruits.  Its intent is to help guide individuals and their departments as they think about promotion to Professor.  This document is not intended to list the elements that every promotion proposal will be expected to address.  The following information is presented for information purposes only and is not intended to create any contract or agreement, and its contents are subject to addition, deletion, and change without prior notice.

Name:

Ravi Salgia, M.D., Ph.D.

 

 

Department of Primary Appointment:

Medicine

 

Secondary appointments:

Pathology

Committee on Cancer Biology

University of Chicago Cancer Research Center

 

Proposed rank:

PROFESSOR

 

Proposed track:

RESEARCH SCHOLAR (TENURE)

DEPARTMENT: What is the candidate's field or specialization?

Dr. Salgia perfoms translational research focused on lung cancer and other solid tumors.

LAY SUMMARY:

Dr. Salgia is a translational scientist, i.e. he carries out research at the bench (as described below) and he takes findings from the research laboratory and applies them to the development of therapies to treat cancers.  Cancers are extremely diverse, and Dr. Salgia focuses on cancers of the lungs, head, and neck.

 

Dr. Salgia initially obtained his BachelorsÕ at Loyola University of Chicago, and he published four first author papers in mathematics as an undergraduate student.  He went on to obtain his MD/PhD at Loyola University of Chicago, where his research focused on membrane abnormalities in a metabolic disorder, GaucherÕs disease, in which an enzyme deficiency causes the accumulation of proteins and a variety of debilitating symptoms.  His internship/residency was at the Johns Hopkins in Internal Medicine.  Finally, he did his Medical Oncology Fellowship at the Dana-Farber Cancer Institute (DFCI)/Harvard Medical School.  During his fellowship, he also worked in the research laboratory of Dr. James D. Griffin, a icon in cancer biology who focuses on leukemias. In Dr. GriffinÕs laboratory, he cloned the gene for the protein paxillin (important cytoskeletal protein) from a leukemia cell line. Dr. Salgia went on to show the importance of paxillin in cell motility/migration for normal blood cells and leukemic cells.

 

As an independent investigator and a physician-scientist, Dr. Salgia has made several major discoveries.  First, he identified mutations of the c-Met receptor tyrosine kinase gene in lung cancer, mesothelioma, and other solid tumors. c-Met is a membrane protein receptor widely expressed in the body that responds to extracellular signals (proteins abbreviated HGF/SF, hepatic growth factor/scatter factor) to tell the cell when to enter the cell cycle (divide) and/or change phenotype.  Not only did he elucidate the biological and biochemical importance of c-Met in lung cancer, but in the laboratory, using cell lines and mouse models, he showed that small molecule inhibitors against c-Met were effective in killing lung cancer, mesothelioma, head and neck cancer, and malignant melanoma cells.  He then helped bring several inhibitors against c-Met to the clinics, and he is the Principal Investigator on these clinical trials at the University of Chicago.  This strategy is now widely embraced as a potentially useful one for the treatment of some cancers.

 

In a second area of study, he has continued to study the role of paxillin in cancer.  Paxillin is one of a number of membrane proteins, called adhesion molecules, which link elements in the extracellular space to the intracellular cytoskeleton.  They are not only linkers, but they have transduction domains that respond to ligands in the extracellular space to trigger enzyme cascades inside cells.  He identified unique mutations of the paxillin gene in lung cancer, and these mutations were not present in mesothelioma, head and neck cancer, melanoma, cervical cancer, or leukemias.  He identified that one of the mutations of paxillin promotes blood vessel formation and distant spread in lung cancer.  He also showed that taking away paxillin from lung cancer cells leads to cell death—an important observation for developing future therapy against lung cancer. 

 

Third, he has also worked with the enzyme topoisomerase-a class of proteins often with altered activity in cancer and targeted by cancer therapies, to show that it could be activated by different receptors than had previously been implicated.  These were surprisingly located at the cell surface in small cell lung cancer.

He has a strong teaching portfolio with outstanding teaching evaluations in all venues in which he teaches, which include not only medical oncology fellows, but also mentoring trainees at multiple levels in the research environment.  He also has a very active clinic in thoracic malignancies (lung cancer, esophageal cancer, mesothelioma, carcinoid tumors, and thymoma), and he sees patients on Wednesday afternoons and Friday mornings. As a clincian he is also extraordinary.  One indication of this is his inclusion on the "Best Doctors in America" list for the past several years.  This independent database is compiled annually based on input from doctors evaluating their peers (http://www.bestdoctors.com/bd/experts.php). 

CURRICULUM VITAE

 

PROFESSIONAL MEMBERSHIPS

1

1993 – pres     American Society of Hematology

1994 – pres     American Society of Clinical Oncology

2000 – pres     American Association for Cancer Research

2001 – pres     International Association for the Study of Lung Cancer

 

 

NATIONAL AND INTERNATIONAL COMMITTEES

2003 –               pres      Academic Advisory Board, PhysiciansÕ Education Resource

2003 –               pres      CALGB, Respiratory Committee Member

2003 –               pres      Reviewer and member, eMedicus Institutional Review Board

2003 –               pres      Advisory Council, American Lung Association

2005 –               pres      Scientific Reviewer, NRSA Study Section, NCI

2006 –               pres      Board of Directors, American Cancer Society, IL

2007 –               pres      Scientific Reviewer, Tumor Progression Metastasis Study Section, NCI

2007 –               pres      Scientific Reviewer, NIEHS P50 Study Section

2007 –               pres      Scientific Reviewer, NCI SPORE

2007 –               pres      Cancer Education Committee, American Society of Clinical Oncology

2007 -              NCI Intramural Research Programs Reviewer, Review of Lab of Molecular                                 Biology

 

HONORS

2002                   Scientific reviewer, Tobacco-related disease research program for California and Colorado study section

2002                   Study Section, ZRG-1, SSS-1

2002                   Scientific reviewer, Italian Association for Cancer Research

2004                   Scientific reviewer, Leukemia Research Foundation

2002 –               pres     Scientific reviewer, DOD, NIH, ACS

2005 – pres     Best Doctors in America

 

TEACHING ACTIVITIES

 

1995 – 2003   Tumor Boards

       Invited speaker and discussant for various New England hospitals

       40 hours/year

 

1994 –               pres Invited speaker and discussant for various hospitals and oncologists throughout the country on novel therapies in lung cancer

       40 hours/year

 

1990 –               pres Basic science and clinical research

       Invited speaker for various academic institutions and national/international meetings

       100 hours/year

 

1994 –               pres Critically review submitted manuscripts for the various journals such as Blood, J Clin Oncol, Cancer Research, Clinical Cancer Research, JEPTO, Oncogene and New England Journal of Medicine

       100 hours/year

 

1998 –               pres Medicine conference and consultations, nationally and internationally in thoracic oncology

       30 hours/year

 

EDITORIAL SERVICES

2002 – pres  Associate Editor, Journal of Environmental Pathology, Toxicology and Oncology

 

Editorial Board Member

2003 –               pres Editorial Advisory Board, Current WomenÕs Health Reviews

PRESENTATIONS

Please note, these are only those since moving to the University of Chicago.

 

INVITED TALKS (within the University and locally)

1.                 "Role of c-Met Receptor Tyrosine Kinase in Lung Cancer," Department of Pathology, University of Chicago, Chicago, IL, 2003.

 

 

2.                  ÒSCLC:  From Molecular Biology to Novel Therapeutics,Ó University of Chicago-Medicine Grand Rounds, Chicago, IL, 2003.

 

3.                 "A Novel Concept for Chemoprevention," Chemoprevention Committee, CALGB, Chicago, IL, September 2003

 

4.                 ÒNovel Therapies in Lung Cancer,Ó Ingalls Hospital-Grand Rounds, Chicago, IL, 2004.

 

5.                 ÒDiscoveries of Targeted Therapies in Lung Cancer,Ó Phase II Consortium, University of Chicago, Chicago, IL, 2004.

 

6.                 ÒNovel Therapies in Lung Cancer,Ó Little Company of Mary Hospital-Grand Rounds, Chicago, IL, 2004.

 

7.                 ÒIn vivo modeling for RTK inhibition in lung cancer and imaging,Ó University of Chicago, Radiology Department, Chicago, IL, 2004.

 

8.                 ÒNovel Therapies in Non-Small Cell Lung Cancer,Ó Mercy Hospital-Grand Rounds, Chicago, IL, 2004.

 

9.                 ÒTargeting c-Met and EGFR in lung cancer,Ó University of Chicago, Mini-symposia, Chicago, IL, 2004.

 

10.             ÒRole of heat shock proteins in lung cancer,Ó University of Chicago, Phase II symposia, Chicago, IL, 2005.

 

11.             ÒNovel therapies in lung cancer,Ó Grand rounds, Evanston Hospital, Evanston, IL, 2005.

 

12.             ÒNovel targeted therapies in lung cancer,Ó Oncology Grand rounds, Cook County Hospital, Chicago, IL, 2005.

 

13.             ÒRole of c-Met/HGF axis in malignancies, with special emphasis on thoracic malignancies,Ó Pathology Lecture series, University of Chicago, IL, 2006.

 

14.             ÒNovel targeted therapies in lung cancer, special emphasis on receptor tyrosine kinases,Ó Grand rounds, Ingalls Hospital, IL, 2006.

 

15.             ÒLung Cancer—From Prevention to Therapy,Ó Invited Presentation from the UCCRC to the Argonne National Laboratories Open House, IL, 2006.

 

16.             ÒProgress in thoracic oncology program,Ó University of Chicago Phase II Consortium, 12th Annual Meeting, Chicago, IL, 2007.

 

17.             ÒLung Cancer—Prevention, Diagnosis and Therapy,Ó South Suburban Hospital, Grand Rounds, American Lung Association, Chicago, IL, 2007.

 

18.             ÒLung Cancer—Diagnosis to Novel Therapy,Ó Roseland Community Hospital, Grand Rounds, American Lung Association, Chicago, IL, 2007.

 

CME PRESENTATIONS

19.             ÒTherapy for Small Cell Lung Cancer,Ó CME Presentation, Houston, TX, 2003.

 

 

20.             ÒTherapy for Lung Cancer,Ó CME Presentation, Indianapolis, IN, 2003.

 

21.             ÒNovel Therapy for Lung Cancer,Ó CME Presentation, New York, NY, 2003.

 

22.             ÒTargeted Therapy for Lung Cancer,Ó CME Presentation, Milwaukee, WI, 2004.

 

23.             ÒDiagnosis and Therapy for SCLC,Ó CME Presentation, Minneapolis, MN, 2004.

 

24.             ÒSCLC:  Challenges to Therapy,Ó CME Presentation, Detroit, MI, 2003.

 

25.             ÒSCLC Therapies,Ó CME Presentation, Fort Wayne, IN, 2004.

 

26.             ÒSCLC,Ó CME Presentation, Louisville, KY, 2004.

 

27.             ÒTargeted Therapies in Lung Cancer,Ó CME Presentation, Joliet Cancer Center, Joliet, IL, 2004.

 

28.             ÒTargeted Therapies in NSCLC,Ó CME Presentation, Fort Wayne, IN, 2004.

 

29.             ÒTherapy for SCLC,Ó CME Presentation, New London Cancer Center, New London, CT, 2004.

 

30.             ÒSCLC—Diagnosis to Therapy,Ó CME Presentation, Springfield, MO, 2004.

 

31.             ÒSCLC,Ó CME Presentation, Grand Rapids, MO, 2004.

 

32.             ÒSCLC,Ó CME Presentation, Omaha, NE, 2004.

 

33.             ÒHer1 targeted therapy in non-small cell lung cancer,Ó CME Presentation, Oak Brook, IL, 2005.

 

34.             ÒUpdate in lung cancer, post-ASCO,Ó CME Presentation, Roswell Park Cancer Institute, Buffalo, NY, 2005.

 

35.             ÒRole and therapeutic targeting of c-Met in lung cancer,Ó CME Presentation, Van Andel Institution, Grand Rapids, MI, 2005.

 

36.             ÒTreatment of small cell lung cancer,Ó CME Presentation, Chicago, IL, 2005.

 

37.             ÒDiagnosis and Therapy of non-small lung cancer,Ó CME Presentation, Rockford, IL, 2005.

 

38.              ÒTherapy for non-small cell lung cancer,Ó CME Presentation, Galesburg, IL, 2005.

 

39.             ÒDiagnosis and therapy for small cell lung cancer,Ó CME Presentation, Springfield, IL, 2006.

 

40.             Host Presenter at the Interactive Roundtable program entitled Relapsed Small Cell Lung Cancer Case Based Discussions, CME Program. Chicago, IL, 2006.

 

41.             ÒTherapy for small cell lung cancer,Ó CME Presentation, IN, 2006.

 

42.             ÒTherapy for non-small cell lung cancer,Ó CME Presentation, Naperville, IL, 2006.

 

43.             ÒTargeted therapies in lung cancer,Ó CME Presentation, Rockford, IL, 2007.

 

44.              ÒNovel therapies in lung cancer,Ó CME Presentation, Joliet Oncology, Joliet, IL, 2007.

 

NATIONAL AND INTERNATIONAL INVITED TALKS

45.             "Basic Science Primer for Molecular Targeted Therapy", Meet the Professor Session, IASLC, Vancouver, Canada, 2003

 

46.             "Neuroendocrine Tumors of the Lung--Novel Therapeutic Approaches," Special Session, IASLC, Vancouver, Canada, 2003

 

47.             "Expression and Modulation of c-Kit and c-Met Receptor Tyrosine Kinases and Downstream Effects on Topoisomerase-I Activity in Small Cell Lung Cancer," IASLC, Vancouver, Canada, 2003

 

48.             "Novel Doublets in Combined Modality Therapy of Non-Small Cell Lung Cancer," Novel Therapies in Thoracic Oncology, University of Minnesota, Minneapolis, MN, 2003

 

49.              ÒNovel Therapies in Lung Cancer,Ó Buffalo Medical Group-Grand Rounds, Buffalo, NY, 2003.

 

50.             ÒRole of Receptor Tyrosine Kinases in Lung Cancer,Ó Roswell Park Cancer Institute-Grand Rounds, Buffalo, NY,  2003.

 

51.             ÒRole of Receptor Tyrosine Kinases and Novel Therapy in Neuroendocrine Tumors,Ó Cold Spring Harbor Laboratory, New York, NY, 2003.

 

52.              Òc-Kit can modulate topoisomerase-I activity in small cell lung cancer,Ó Presentation, The American Cancer Society, Harry and Elsa Jiler—American Cancer Society Professors Meeting, Key Biscayne, FL, 2003.

 

53.              ÒRole of c-Met Receptor Tyrosine Kinase in Lung Cancer, with Potential for Novel Therapy,Ó Zurich, Switzerland, 2003.

 

54.             ÒRole of c-Met Receptor Tyrosine Kinase in Lung CancerÓ, University of Minnesota, 2004.

 

55.              ÒNovel Therapies in Lung Cancer—From Bench to Bedside,Ó Grand Rounds, Christ Hospital, Chicago, IL, 2004.

 

56.              ÒSCLC—From Biology to Therapy,Ó Fort Wayne Hospital-Grand Rounds, Ft. Wayne, IN, 2004.

 

57.              ÒVaccine Therapies for Lung Cancer,Ó Presentation for Targeted Therapies for the Treatment of Lung Cancer (Organizers, P. Bunn, D. Johnson, and R. Herbst), San Diego, CA, 2004.

 

58.             ÒRole of c-Met in Lung Cancer,Ó Roswell Park Cancer Institute-Grand Rounds, Buffalo, NY, 2004.

 

59.              ÒOverview of Treatment for Advanced/Metastatic NSCLC, Cytotoxic Chemotherapy,Ó and ÒCALGB Trials for Combined Modality Therapy for Locally Advanced NSCLC,Ó Presentation for The 1st WJTOG International Symposium on Lung Cancer Clinical Trial (Organizers, Y. Ariyoshi, M. Fukuoka, and K. Eguchi), Nara, Japan, 2004.

 

60.             ÒNovel Targeted Therapies in Lung Cancer,Ó Lung Cancer Symposium (Org, T. Lynch), Chicago, IL, 2004.

 

61.              ÒReceptor tyrosine kinases can target topoisomerase-I, a novel approach for SCLC therapy,Ó Advances in Thoracic Oncology (Org, R. Salgia), Chicago, IL, 2004.

 

62.             Òc-Met in lung cancer,Ó Met Summit, San Diego, CA, 2004.

 

63.             ÒPhospho-Regulation of the c-MET/HGFR Signaling Pathway in Human Cancer,Ó 12th International Conference on Second Messengers and Phosphoproteins, Montreal, Canada, 2004.

 

64.             ÒNovel Therapies in Non-Small Cell Lung Cancer,Ó Sisters of Charity-Grand Rounds, Buffalo, NY, 2004.

 

65.             ÒRole of c-Met in lung cancer,Ó Plenary Session, Asian-Pacific Conference of Tumor Biology and Medicine & 21st IATMO Conference (Also, Scientific Co-Organizer and Session Chair), XiÕAn, China, 2004.

 

66.             ÒPlatins in lung cancer,Ó Chicago Symposium on Cancer, Chicago, IL, 2004.

 

67.             ÒMolecular characteristics and genomics of mesothelioma, and the role of c-MET,Ó IASLC Meeting on Mesothelioma (Org, R. Stahel and H. Kindler), Weinfelden, Switzerland, 2004.

 

68.             Òc-Met in lung cancer,Ó  3rd International Chicago Symposium on Malignancies of the Chest Head & Neck (Also, co-organizer), Chicago, IL, 2004.

 

69.              ÒHGF/c-MET in Cancer,Ó 7th International Conference of Anticancer Research (also scientific co-organizer and chair of session on novel therapies), Corfu, Greece, 2004.

 

70.             Òc-Met and its potential for inhibition in cancer,Ó La Jolla Symposium, La Jolla, CA, 2004.

 

71.              ÒUnderstanding HER-1/EGFR-Targeted Therapies in the Treatment of NSCLC and Other Solid Tumors,Ó CME Presentation, South Bend, IN, 2005.

 

72.             ÒSecond line therapies for NSCLC,Ó CME Presentation, Naperville, IL, 2005.

 

73.             ÒRole of c-Met in lung cancer,Ó RTK Symposium, San Diego, CA , 2005.

 

74.             ÒHeat shock proteins in lung cancer,Ó Novel Target Symposium, Boston, MA, 2005.

 

75.              Òc-Met as a target in malignancies,Ó XXIV Annual Symposium Cancer Development and Progression, University of Montreal, Canada, 2006.

 

76.             ÒChemoprevention of lung cancer,Ó Lung Cancer Prevention and Surveillance Symposium, Chicago, IL, 2006.

 

77.             ÒAnti-Angiogenic therapy in non-small cell lung cancer,Ó Post-ASCO Highlights, Sattelite Symposium, Atlanta, GA, 2006.

 

78.             ÒRole of c-Met in lung cancer,Ó Oncology grand rounds, Feist-Weiller Cancer Center, Louisiana State University, Shreveport, LA, 2006.

 

79.              ÒNovel therapies in lung cancer,Ó 11th Annual Phase II Symposium, Gleacher Center, University of Chicago, IL, 2006.

 

80.             ÒRole and therapeutic inhibition of c-Met in lung cancer,Ó  AACR Annual Meeting, Special Symposium: Beyond EGFR and VEGF: New Targets and Pathway Signatures in the Development of Lung Cancer Therapy, Washington, D.C., 2006.

 

81.             ÒNovel targets in lung cancer,Ó  Novel therapy scientific symposium, San Francisco, CA, 2006.

 

82.             ÒTargeting c-Met in lung cancer,Ó Lung Cancer Winter SPORE meeting, CA, 2006.

 

83.              ÒAntiangiogenic therapies in lung cancer,Ó Future of Lung Symposium, Washington, DC, 2006.

 

84.              Òc-Met as a novel target for therapy,Ó Rockland, MD, 2006.

 

85.             ÒRole of c-Met in lung cancer,Ó The 2006 NCRI Cancer Conference held at the ICC, Birmingham, UK, 2006.

 

86.             ÒTargeted therapies in lung cancer,Ó CME Presentation, Oak Brook, IL, 2006.

 

87.             "Applications for solid tumors as related to the C-Met Gene," Van Andel Symposium, Grand Rapids Clinical Oncology Program, Grand Rapids, MI, 2006.

 

88.             ÒRole of c-Met and Paxillin in Head and Neck Cancer,Ó H&N SPORE Meeting, Chicago, IL, 2006.

 

89.             ÒRole of c-Met in lung cancer,Ó The First JCA-AACR Special Joint Conference. (Chair, Novel Therapy Session), Nagoya Japan, 2007.

 

90.             Òc-Met as a therapeutic target in tumors, especially lung cancer,Ó IASLC-SPORE Meeting, CA, 2007.

 

91.              Òc-Met as a therapeutic target in lung cancer,Ó AACR, Los Angeles, CA, 2007.

 

92.              Òc-Met as a therapeutic target in malignancies, with particular emphasis on lung cancer,Ó Gordon Conference, NH, July, 2007.

 

93.             ÒChemokine/chemokine receptors in lung cancer,Ó ISOBM Conference, Prague, Czech Republic, September, 2007.

 

94.             Òc-Met and EGFR as predictive and prognostic markers in lung cancer,Ó IASLC, Seoul, Korea, September, 2007.

 

95.             ÒMet inhibition,Ó 6th International Symposium on Translational Research in Oncology, Dublin, Ireland, October, 2007.

 

Conference and Symposium Organization, Session Chair, and Abstract Reviews

 

96.             ÒInternational Association for Lung Cancer, Novel Targeted Therapies,Ó Abstract Reviewer, Vancouver, Canada, 2004.

 

97.             ÒAdvances in Thoracic Oncology at the University of Chicago,Ó Principal Organizer, Chicago, IL, 2004.

 

98.             ÒThe Third International Chicago Symposium on Malignancies of the Chest and Head and Neck,Ó Symposium Executive Committee, 2004.

 

99.             ÒThe 1st WJTOG International Symposium on Lung Cancer Clinical Trial,Ó Sessions Chair (1.  Treatment for Advanced/Metastatic NSCLC, Cytotoxic Chemotherapy; 2.  Treatment for the Elderly/PS2 Patients with NSCLC), Nara, Japan, 2004 (Organizers Y. Ariyoshi, MD; M. Fukuoka, MD; K. Eguchi, MD).

 

100.         ÒSeventh International Conference of Anticancer Research,Ó Organizing committee, Corfu, Greece, 2004.

 

101.         ÒMini-Symposia on Novel Therapies in Lung Cancer,Ó Principal Organizer, University of Chicago, Chicago, IL, 2004.

 

102.         ÒInternational Association for Lung Cancer, Novel Targeted Therapies,Ó Abstract Reviewer and Session Chair, Barcelona, Spain, 2005.

 

103.         ÒUpdate on Thoracic Malignancies, Ò Principal Organizer, Chicago, IL 2005.

 

104.         ÒLung Cancer Prevention and Surveillance: An Update,Ó Director, Chicago, IL 2006.

 

105.         ÒNovel Targets in Diseases, Role of c-Met,Ó Director, International Symposia held at the University of Chicago, Chicago, IL, 2006.